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LETTERS TO THE EDITOR
  Statin Use and 
Survival in Resectable 
Pancreatic Cancer: 
Confounders and 
Mechanisms
 Livia  Archibugi ,  MD 1 ,  Gabriele  Capurso , 
 MD, PhD 1 and  Gianfranco  Delle Fave ,  MD 1 
 doi: 10.1038/ajg.2015.412 
 To the Editor: We read with great interest 
the paper by Wu  et al. ( 1 ) demonstrating 
that, among patients with surgically treated 
pancreatic cancer, statin users, especially 
those employing moderate-to-high dos-
ages of simvastatin, had a signifi cantly 
improved overall survival, also when this 
was adjusted for multiple confounders. 
Th is is an interesting fi nding, confi rmed 
by similar recent results from the SEER-
Medicare database ( 2 ). Although we agree 
that the use of statins in patients operated 
for pancreatic cancer merits further inves-
tigation, we think that some additional 
points might need discussion to help 
clarifying the authors’ fi ndings.
 A fi rst point regards the possible activity 
of drugs other than statins, such as aspirin 
or metformin, against pancreatic cancer. 
As many patients use a combination of 
these drugs, one might speculate that the 
association between simvastatin and over-
all survival in resected pancreatic cancer 
patients might also be explained by the 
concomitant use of aspirin or metformin, 
or that these drugs might result synergis-
tic, as hypothesized for colorectal cancer 
( 3 ). We wonder whether the authors had 
access to data on aspirin or metformin use 
for their population.
 A second point regards the very high 
45% rate of simvastatin or lovastatin users 
reported by the authors. Th is fi gure is dif-
ferent from that of many European coun-
tries, thus possibly limiting the attributable 
fraction of cases for whom the observed 
fi ndings can be replicated.
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 De novo Malignancy 
and Recurrent Alcoholic 
Cirrhosis Account for 
70% of Deaths in 
Patients Transplanted 
for End-Stage Alcoholic 
Liver Disease
 Jef  Verbeek ,  MD, PhD 1 , 2 ,  David  Cassiman , 
 MD, PhD 1 and  Frederik  Nevens ,  MD, PhD 1 
 doi: 10.1038/ajg.2016.10 
 To the Editor: We read the article by 
Dumortier  et al. ( 1 ) with interest. Th is 
elegant study, in a large number of patients 
with a long-term follow-up, raises the con-
cern regarding recurrent alcoholic cirrho-
sis (RAC) aft er liver transplantation (LTx) 
for end-stage alcoholic liver disease (ALD).
 In our single center study, 204 patients 
were transplanted for ALD between 1994 
and 2011, of which 193 patients survived 
>6 months aft er LTx ( 2 ). Mean follow-up 
aft er LTx was 5 years. A total of 27.5% 
(53/193) of the patients had an alcoholic 
relapse defi ned as any alcohol use. In sup-
port of the fi ndings by Dumortier  et al. 
( 1 ), 7.5% (4/53) of them developed biopsy 
proven RAC, despite our signifi cantly 
shorter follow-up aft er LTx.
 However, as briefl y touched by the 
authors,  de novo malignancy and not RAC 
is the major determinant of mortality in 
patients transplanted for ALD. In our 
 We interrogated our single-center data-
base of 356 consecutive pancreatic cancer 
patients to analyze these two issues and 
found no protective eff ect of the use of 
either statins, aspirin, metformin, or any 
of their combination in terms of overall 
survival. As expected, however, only 17.7% 
of our patients used statins (5.6% simvas-
tatin). Notably, when considering only 85 
resected patients, still no diff erence was 
found between active users and non-users 
of statins (hazard ratio (HR) 1.06; 95% 
confi dence interval (CI) 0.5–2.2) or aspirin 
(HR 0.9; 95% CI 0.4–1.9), metformin (HR 
0.45; 95% CI 0.04–4.2), or statin and aspirin 
combination (HR 0.54; 95% CI 0.2–1.4).
 Finally, as far as the mechanisms by 
which simvastatin might improve survival, 
the authors do not cite the possible direct 
eff ect on the risk of venous thromboembo-
lism. Venous thromboembolism is a rather 
frequent event in patients with pancreatic 
cancer, with serious consequences also 
in terms of survival, and the use of both 
statins and aspirin seems to reduce this 
risk in cancer patients ( 4 ).
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